Last updated: August 25, 2026
Teveten, the brand name for eprosartan mesylate, is a mature angiotensin II receptor blocker that has largely exited the U.S. commercial market. Its financial trajectory followed the standard pattern for a late-entry antihypertensive: regulatory approval and branded positioning, limited differentiation within a crowded ARB class, loss of exclusivity, generic price erosion, and eventual commercial discontinuation. Public filings do not report Teveten revenue separately, so no reliable standalone sales series exists.
What is Teveten and how was it positioned?
Teveten contains eprosartan mesylate, an oral angiotensin II type 1 receptor antagonist used to treat hypertension. The U.S. Food and Drug Administration approved Teveten for hypertension in 1997. A fixed-dose combination, Teveten HCT, combined eprosartan with hydrochlorothiazide.[1]
Eprosartan was positioned against established and rapidly expanding ARB brands, including:
- Cozaar, losartan, marketed by Merck
- Diovan, valsartan, marketed by Novartis
- Avapro, irbesartan, marketed by Bristol-Myers Squibb and Sanofi
- Atacand, candesartan, marketed by AstraZeneca
- Micardis, telmisartan, marketed by Boehringer Ingelheim
The drug’s pharmacology offered a conventional AT1-receptor blockade mechanism. Its differentiation was limited from a commercial standpoint because physicians could select among several ARBs with comparable hypertension indications, broader clinical familiarity, stronger marketing resources, or greater formulary presence.
Eprosartan also had a claimed effect on presynaptic angiotensin II receptors that could reduce sympathetic norepinephrine release. That feature supported scientific differentiation but did not create a durable pricing advantage.[1]
What were Teveten’s key FDA milestones?
| Milestone |
Date or status |
| U.S. approval of Teveten |
1997 |
| Active ingredient |
Eprosartan mesylate |
| Primary indication |
Hypertension |
| Fixed-dose combination |
Eprosartan/hydrochlorothiazide |
| U.S. regulatory status |
FDA records classify Teveten products as discontinued |
| Biologic status |
Not applicable |
| Reference product type |
Small-molecule prescription drug |
The Teveten approval was based on antihypertensive efficacy demonstrated in clinical studies. The FDA labeling covered monotherapy and dose escalation, with the usual safety considerations for renin-angiotensin system inhibitors, including hypotension, renal impairment, and hyperkalemia.[1]
Teveten did not obtain the kind of broad cardiovascular outcome positioning that helped some competing ARBs maintain commercial relevance. The drug was evaluated in cardiovascular research, including the MOSES study, which compared eprosartan with nitrendipine in patients with hypertension and cerebrovascular disease. MOSES reported fewer cerebrovascular and cardiovascular events with eprosartan in the studied population, but the trial did not transform Teveten into a leading global ARB franchise.[2]
When did Teveten lose exclusivity?
Teveten’s core U.S. composition-of-matter and regulatory exclusivity period ended many years ago. The product is now a post-exclusivity medicine, and the commercial question is no longer whether generic entry is permitted but whether any manufacturer has sufficient demand and margin to maintain active marketing.
The relevant loss-of-exclusivity sequence was:
- U.S. approval in 1997.
- Expiration of the original patent and regulatory exclusivity protections during the following decade.
- Increasing generic substitution across the ARB class.
- Declining branded formulary access.
- U.S. commercial discontinuation of Teveten and Teveten HCT.
The FDA Orange Book remains the principal source for current U.S. listed patents, exclusivity and reference-product status.[3] Teveten’s commercial life is not protected by a currently valuable U.S. patent estate. The main commercial barriers are demand, manufacturing economics and distribution, rather than enforceable exclusivity.
What patents protect Teveten?
Teveten was protected historically by patents covering eprosartan, pharmaceutical compositions and related formulations. The commercially important protection was the active-ingredient patent estate, not a durable lifecycle strategy built around multiple differentiated formulations.
The remaining patent value is limited for four reasons:
- The product was approved in 1997.
- The relevant exclusivity period has expired.
- The FDA classifies the branded U.S. product as discontinued.
- Antihypertensive prescribing has shifted toward low-cost generic ARBs.
No active, high-value Teveten patent position is generally recognized as a current U.S. market barrier. Any patent analysis for a specific country would require review of national registers because expiration dates, supplementary protection certificates and abandonment records vary by jurisdiction.
Are formulation patents still important for Teveten?
Formulation patents are not a meaningful current commercial driver for Teveten in the United States. Teveten HCT created a fixed-dose product opportunity, but combination therapy in hypertension became highly competitive. Generic manufacturers could compete through separate component tablets, authorized or conventional fixed-dose combinations, and therapeutic substitution.
The fixed-dose formulation did not produce a durable secondary exclusivity platform comparable with newer delivery technologies, long-acting injectables or complex-release systems.
What is the Orange Book status of Teveten?
The FDA Orange Book and Drugs@FDA records are central to Teveten’s U.S. status. Teveten was approved under NDA 20-386, while Teveten HCT was approved under a separate application.[1,3]
The commercial interpretation is straightforward:
- Teveten is a small-molecule reference drug.
- It is not a biologic and has no biosimilar pathway.
- FDA records identify the product as discontinued.
- The discontinuation does not by itself establish a safety withdrawal.
- No current branded revenue base should be assumed from the historical approval.
A discontinued branded product can remain relevant as a reference product for regulatory or patent analysis, but it does not necessarily support active sales, marketing or supply.
Which companies challenged Teveten’s exclusivity?
Teveten did not generate a prominent U.S. Paragraph IV litigation profile comparable with major blockbuster drugs. Publicly visible commercial evidence points to ordinary post-exclusivity erosion rather than a high-value patent dispute that materially delayed generic competition.
Paragraph IV risk was structurally low by the time the product became commercially marginal. A generic applicant could challenge any remaining listed patent, but the expected return would have been constrained by:
- Small and declining branded demand.
- Low prices across the ARB category.
- Established competition from other generic ARBs.
- Limited incentive to fund extensive litigation.
- Possible manufacturing and distribution costs exceeding expected gross profit.
The absence of major public litigation is commercially important. It indicates that Teveten’s decline was driven more by market economics and therapeutic substitution than by a prolonged legal defense.
How did Teveten compare with competing ARBs?
| Drug |
Active ingredient |
Commercial position |
Competitive advantage |
| Teveten |
Eprosartan |
Niche, discontinued in the U.S. |
Limited differentiation |
| Cozaar |
Losartan |
Major early ARB brand; extensive generic use |
First-mover scale and broad familiarity |
| Diovan |
Valsartan |
Major branded franchise |
Strong cardiovascular positioning and sales force |
| Avapro |
Irbesartan |
Established hypertension franchise |
Clinical familiarity and broad generic uptake |
| Atacand |
Candesartan |
Strong cardiovascular and heart-failure profile |
Outcome data and physician adoption |
| Micardis |
Telmisartan |
Established multinational brand |
Long half-life and later cardiovascular positioning |
Teveten’s principal weakness was timing. It entered a class that already had strong competitors and then faced generic erosion before it could establish a distinctive, high-value clinical niche.
The ARB market also benefited from class-level generic substitution. Once physicians and payers accepted generic losartan, valsartan, irbesartan and candesartan, a lesser-known branded ARB faced limited pricing power.
What was Teveten’s financial trajectory?
No major manufacturer has historically reported Teveten revenue as a standalone line item. Solvay and later Abbott reported pharmaceutical results at broader business-unit levels, which prevents a reliable product-specific revenue reconstruction.[4,5]
The financial trajectory can therefore be assessed through market structure rather than reported brand sales:
Launch and early commercialization
The launch phase generated conventional branded revenue from an approved antihypertensive with an established therapeutic class. Solvay had a commercial presence in cardiovascular medicines, but Teveten did not reach the scale of leading ARB franchises.
Mature branded period
Revenue was constrained by:
- Multiple branded ARB competitors.
- Physician familiarity with other agents.
- Formulary competition.
- Limited evidence of a broad outcome-based premium.
- Increasing use of fixed-dose combinations and generic alternatives.
Teveten HCT likely supported incremental prescribing in combination therapy, but the combination did not create a major independent franchise.
Post-exclusivity period
After loss of exclusivity, branded price and volume would have faced the standard dual pressure of generic substitution and payer restrictions. In a hypertension market, these pressures are particularly strong because treatment is chronic, alternatives are abundant and therapeutic switching is usually straightforward.
Discontinuation
The FDA’s discontinued-product classification indicates that the U.S. product no longer represented a meaningful active commercial platform.[3] The likely economic rationale was straightforward: expected net sales no longer justified manufacturing, regulatory maintenance, sales support and distribution.
What manufacturing and intellectual-property barriers remain?
The active ingredient is a conventional small molecule rather than a complex biologic or advanced delivery system. Manufacturing barriers are therefore manageable in technical terms but can still be significant economically.
Potential barriers include:
- Limited demand for a discontinued or niche product.
- Minimum batch sizes.
- API sourcing and quality-system costs.
- Stability and packaging requirements.
- Regulatory maintenance for legacy products.
- Distributor and pharmacy-channel fees.
- Competition from lower-cost ARB alternatives.
The commercial barrier is not difficult chemistry. It is insufficient market scale. A manufacturer could face negative or minimal contribution margins even if it could produce eprosartan tablets efficiently.
Is there biosimilar risk for Teveten?
No. Biosimilar risk does not apply because Teveten is a small-molecule drug. The relevant competitive mechanisms are generic substitution, ANDA approval, therapeutic interchange and price competition.
This distinction matters for valuation. Teveten does not have biologic manufacturing complexity, interchangeable-biologic rules or biosimilar development costs. Its risk profile is closer to a legacy oral generic with limited demand.
What licensing deals affected Teveten?
The most important corporate transaction affecting Teveten was Abbott’s acquisition of Solvay Pharmaceuticals, completed in 2010. Abbott acquired Solvay’s pharmaceutical portfolio, including established products and regional assets.[5]
The transaction did not create a new growth platform for Teveten. By that stage, the drug was a mature antihypertensive facing class-wide generic pressure. Abbott’s strategic value from the Solvay acquisition came from the broader portfolio and geographic footprint, not from Teveten as a standalone growth asset.
No major recent licensing transaction has established meaningful new value for Teveten.
What generic launch risks exist for Teveten?
A generic launch would face low legal risk but high commercial risk. The principal scenarios are:
| Scenario |
Market effect |
Probability assessment |
| No new U.S. generic launch |
Product remains commercially inactive |
Most consistent with discontinued status |
| Limited generic re-entry |
Supply serves narrow or institutional demand |
Possible but economically constrained |
| Broad generic relaunch |
Price competition and rapid substitution |
Unlikely without clear demand |
| Brand revival |
Requires new clinical or commercial positioning |
Low probability |
A manufacturer seeking re-entry would need to establish stable demand from wholesalers, hospitals, managed-care plans or international markets. The absence of a strong branded base reduces the value of a traditional generic launch.
How strong is the Teveten patent estate?
Teveten’s current patent strength is low. Its historical patent estate supported the original branded business, but those rights no longer provide a meaningful U.S. exclusivity moat.
| Patent-estate factor |
Assessment |
| Core compound protection |
Expired or commercially exhausted |
| Formulation protection |
Limited current value |
| Method-of-use protection |
No known commercially decisive active barrier |
| Orange Book leverage |
Low |
| Paragraph IV exposure |
Low-value litigation target |
| Manufacturing know-how |
Technically manageable |
| Commercial defensibility |
Weak |
The remaining value is primarily regulatory and historical. It is not a platform asset with a realistic path to premium pricing.
What is Teveten’s geographic market outlook?
Teveten’s geographic position varies by country. National marketing status, reimbursement, patent records and generic availability can differ across the United States, European markets, Japan and other jurisdictions.
The broad pattern is consistent:
- Mature hypertension markets favor low-cost generic ARBs.
- Brand retention depends on local reimbursement and physician habits.
- Discontinuation in one country does not automatically terminate all international supply.
- A country-specific opportunity would depend on active registration and local demand.
- Patent expiry is generally less important than commercial availability and payer coverage.
The United States should be treated as a discontinued or commercially inactive branded market. Any residual international opportunity is likely to be regional and niche rather than a global growth opportunity.
Key Takeaways
- Teveten is eprosartan mesylate, an ARB approved by the FDA in 1997.
- Its U.S. branded commercial trajectory is effectively complete.
- Public filings do not disclose reliable standalone Teveten revenue.
- The drug lost commercial protection after expiration of its historical exclusivity.
- The Orange Book and FDA records classify the U.S. product as discontinued.
- Teveten faced strong competition from losartan, valsartan, irbesartan, candesartan and telmisartan.
- No biosimilar issue applies; competitive risk is generic substitution.
- The product’s current value is limited by demand and margin, not manufacturing complexity.
- Abbott’s acquisition of Solvay transferred the product but did not create a new growth cycle.
- A generic relaunch would face low patent risk but weak economic incentives.
FAQs
Is Teveten still available in the United States?
FDA records classify Teveten products as discontinued. It should not be treated as an active U.S. branded growth product.[3]
What is the generic name of Teveten?
The generic name is eprosartan mesylate. Teveten HCT contains eprosartan mesylate and hydrochlorothiazide.
Does Teveten have biosimilar competition?
No. Eprosartan is a small-molecule drug, so the relevant competition is from generics rather than biosimilars.
Was Teveten withdrawn for safety reasons?
The FDA discontinued-product classification does not by itself indicate a safety withdrawal. The commercial record is more consistent with product discontinuation after maturity and loss of economic viability.[3]
Could Teveten become commercially relevant again?
A broad revival is unlikely without a new regulatory indication, clinical differentiation or a specialized market opportunity. Existing hypertension alternatives and low generic pricing make a conventional brand relaunch unattractive.
References
- U.S. Food and Drug Administration. (1997). Teveten (eprosartan mesylate) prescribing information. Drugs@FDA.
- Schrader, J., Lüders, S., Kulschewski, A., et al. (2005). Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of the MOSES study. Stroke, 36(6), 1218-1226.
- U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Solvay S.A. (2009). Annual report 2009.
- Abbott Laboratories. (2010). Annual report 2010.
